BRCA1/2, ATM Mutations ID Risk for Lethal Prostate Cancer

Share this content:
<i>BRCA1/2</i>, <i>ATM</i> Mutations ID Risk for Lethal Prostate Cancer
BRCA1/2, ATM Mutations ID Risk for Lethal Prostate Cancer

FRIDAY, Dec. 16, 2016 (HealthDay News) -- The rate of germline BRCA1/2 and ATM mutations is significantly higher among patients with lethal prostate cancer (PCa) and is an independent predictor of lethal PCa, according to a study published online Dec. 15 in European Urology.

Rong Na, from Fudan University in Shanghai, and colleagues directly assessed whether germline mutations in BRCA1/2 and ATM distinguish lethal from indolent PCa. Data were included from a retrospective study of 313 patients who died of PCa and 486 with low-risk localized PCa of European, African, and Chinese descent. Germline DNA from all patients was sequenced for these genes.

The researchers found that lethal PCa patients had a significantly higher combined BRCA1/2 and ATM mutation rate compared with localized PCa patients (6.07 versus 1.44 percent; P = 0.0007). Among lethal PCa patients the rate also differed significantly as a function of age at death (P = 0.046) and time to death after diagnosis (P = 0.0006). After adjustment for race and age, prostate-specific antigen, and Gleason score at the time of diagnosis, being a mutation carrier remained an independent predictor of lethal PCa (hazard ratio, 2.13; P = 0.004).

"Mutation status of BRCA1/2 and ATM distinguishes risk for lethal and indolent PCa and is associated with earlier age at death and shorter survival time," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »